Zio

Name

Zio

Legal name

iRhythm Technologies, Inc.

Website

https://irhythmtech.co.uk

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Ambulatory Cardiac Monitoring

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)

akta.pro secondary industry

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

• Ambulatory cardiac monitoring
• ECG patch monitoring
• Arrhythmia detection
• Cardiac diagnostics
• AI cardiac monitoring

Headquarters

HQ city

Bagshot

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Cardiac Monitoring Service: Zio provides a complete ambulatory cardiac monitoring solution combining single-use hardware patches with AI-powered analysis services. Revenue is generated through the provision of monitoring devices and associated diagnostic reporting services to healthcare providers and patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Zio (by iRhythm Technologies) provides an ambulatory cardiac monitoring solution centered on the Zio XT, a single-use adhesive ECG patch worn for up to 14 days for continuous heart-rhythm recording. The patch is paired with AI-powered analysis that detects cardiac arrhythmias and delivers clinician reports, supported by the ZioSuite patient management portal for healthcare providers.

Product overview

Zio is a cardiac monitoring platform built around the Zio XT patch device and The Zio Service. The core offering consists of a single-use 14-day ambulatory cardiac monitoring patch (Zio XT) paired with an AI-powered service for arrhythmia detection. Additional components include an Artificial Intelligence module for precision analysis, the ZioSuite Patient Management Portal for healthcare provider workflow management, and dedicated Monitoring and Reporting modules for clinicians. The solution is NICE recommended for detecting cardiac arrhythmias.

Differentiator

Problem solved

Functional benefit

Brands

• Zio XT: Premier heart monitoring patch and device for arrhythmia detection; single-use cardiac monitoring powered by AI technology, worn for up to 14 days
• ZioSuite
• ZioService

Products and services

• Zio XT A single-use ambulatory cardiac monitoring patch that records continuous ECG data for up to 14 days, designed to detect cardiac arrhythmias in patients prescribed by clinicians.
• The Zio Service A complete ambulatory cardiac monitoring solution combining the Zio XT patch device with AI-powered analysis and clinician reporting services for healthcare providers and their patients.
• ZioSuite Patient Management Portal A web-based patient management portal that allows healthcare providers to enroll, manage, and review patients using the Zio cardiac monitoring service.

Quantifiable outcome

• 98% patient compliance rate vs industry standard for conventional monitors
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

One partnership is on record.

• National Institute for Health and Care Excellence (NICE)coreOthersNICE has recommended Zio XT for detecting cardiac arrhythmias (MTG52 guidance). This recommendation appears in the latest CVD impact report. NICE is a UK government body that provides national guidance on health and social care, making this a regulatory/clinical endorsement rather than a commercial partnership.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Eko Health: Eko Health produces AI-enabled digital stethoscopes with ECG and cardiac auscultation analysis. While not a direct patch competitor, it overlaps in AI-driven cardiac rhythm analysis and increasingly addresses the same clinician workflow of arrhythmia detection.
• AliveCor (KardiaMobile): AliveCor makes KardiaMobile, a consumer/clinical single-lead ECG device for arrhythmia detection. It is an emerging player that competes for low-acuity screening and consumer self-monitoring, somewhat overlapping with Zio's longer-duration monitoring use case.

Broad incumbents

• Apple (Apple Watch ECG): Apple Watch includes an FDA-cleared ECG feature for AFib detection. While not a peer for prescribed extended monitoring, it influences consumer and clinician expectations around single-lead ECG and is an emerging alternative for low-acuity screening.
• Medtronic (LINQ II insertable cardiac monitor): Medtronic's LINQ II is an insertable cardiac monitor (ICM) for long-term arrhythmia monitoring, often used for cryptogenic stroke workups and AFib detection. It is a peer for extended-duration cardiac monitoring but is invasive/implantable, representing a higher-acuity alternative to the Zio patch.
• GE Healthcare (Holter monitors): GE Healthcare sells traditional Holter monitoring systems and event recorders (SEER series) used by hospitals and clinics. It is a broad incumbent in cardiac diagnostics whose installed base competes for the same monitoring budget as Zio XT.
• Abbott (CardioMEMS / Confirm Rx): Abbott offers Confirm Rx, an insertable cardiac monitor, and broader cardiac diagnostics portfolio. It competes for the cardiology monitoring budget and is a broad incumbent in cardiac rhythm management alongside Zio's ambulatory patch.

Direct peers

• Boston Scientific (Preventice Solutions): Boston Scientific acquired Preventice Solutions and its BodyGuardian Heart remote monitoring patch. It competes with Zio XT in the ambulatory cardiac monitoring segment with patch-based continuous ECG recording and AI-assisted reporting.
• iRhythm Technologies (Zio) - subject company: Zio is iRhythm Technologies' own brand; identifying the parent confirms this is the iRhythm Technologies entity. As a self-reference, omitted in practice.
• Hillrom / Baxter (Bardy Diagnostics): Hillrom (now part of Baxter) acquired Bardy Diagnostics, maker of the Carnation Ambulatory Monitor patch. It is a direct competitor offering a single-use adhesive patch ECG monitor targeting the same cardiology and electrophysiology customers.
• Philips (BioTel): Philips' BioTel division is the largest incumbent in ambulatory cardiac monitoring (event monitors, Holter, MCT). It directly competes with Zio XT in the same clinician customer base with overlapping 14-day patch / MCT solutions, making it the closest direct peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/iRhythm_UK

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zio